|
Market Closed -
Other stock markets
|
After hours 15:59:07 | |||
| 1.556 EUR | -1.39% |
|
1.561 | +0.32% |
| 07-21 | Innate Pharma Completes Enrollment in Dose Escalation of Phase 1 Study of IPH4502 | CI |
| 07-21 | Innate Pharma Closes Enrollment in Phase 1 Advanced Solid Tumors Study | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bullish | Neutral |
| Resistance | 1.71 | 1.96 | 2.01 |
| Spread/Res. | -9.01% | -20.61% | -22.59% |
| Spread/Supp. | +3.60% | +10.35% | +44.88% |
| Support | 1.502 | 1.41 | 1.074 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- IPH Stock
- Charts Innate Pharma
Select your edition
All financial news and data tailored to specific country editions
